A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

ClinicalTrials.gov ID: NCT00081484

Public ClinicalTrials.gov record NCT00081484. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label Study of the Effect of Maintenance Mircera Administered With Pre-filled Syringes on Hemoglobin Levels in Anemic Dialysis Patients With Chronic Kidney Disease

Study identification

NCT ID: NCT00081484
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 336 participants

Conditions and interventions

Conditions

Anemia

Interventions

epoetin alfa or beta Drug
methoxy polyethylene glycol-epoetin beta [Mircera] Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2004
Primary completion: Feb 28, 2006
Completion: Feb 28, 2006
Last update posted: Nov 1, 2016

2004 – 2006

United States locations

U.S. sites: 31
U.S. states: 16
U.S. cities: 26

Facility	City	State	ZIP	Site status
Not listed	Covina	California	91723	—
Not listed	Los Alamitos	California	90720	—
Not listed	Los Angeles	California	90073	—
Not listed	San Diego	California	92123	—
Not listed	San Diego	California	92161	—
Not listed	Tampa	Florida	33617	—
Not listed	Honolulu	Hawaii	96813	—
Not listed	South Holland	Illinois	60473	—
Not listed	Baton Rouge	Louisiana	70884	—
Not listed	Shreveport	Louisiana	71101	—
Not listed	Shreveport	Louisiana	71103	—
Not listed	Boston	Massachusetts	02135	—
Not listed	Kalamazoo	Michigan	49007	—
Not listed	Columbus	Mississippi	39705	—
Not listed	Tupelo	Mississippi	38801	—
Not listed	St Louis	Missouri	63128	—
Not listed	Hackensack	New Jersey	07601	—
Not listed	Flushing	New York	11355	—
Not listed	New York	New York	10025	—
Not listed	Orchard Park	New York	14127	—
Not listed	Cleveland	Ohio	44109	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Oregon City	Oregon	97045	—
Not listed	Erie	Pennsylvania	16502	—
Not listed	Lewistown	Pennsylvania	17044	—
Not listed	Philadelphia	Pennsylvania	19106	—
Not listed	Philadelphia	Pennsylvania	19140	—
Not listed	Philadelphia	Pennsylvania	19141	—
Not listed	Columbia	South Carolina	29209	—
Not listed	Charlottesville	Virginia	22908	—
Not listed	Norfolk	Virginia	23507-1901	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00081484, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Jul 24, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00081484 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →